Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)
These synthetic analogs are also chemically modified to resist enzymatic degradation, allowing them to remain active in your bloodstream for hours to days rather than minutes
HOW SHOULD THE 20MG VIAL BE STORED AND RECONSTITUTED
Administering it subcutaneously once daily, particularly before sleep, aims to mimic the body's natural pulsatile GH secretion patterns
The provision of information by physicians, medical professionals, etc